Beneficial Effects of Selective Orexin-A Receptor Antagonist in 4-aminopyridine-induced Seizures in Male Rats

Hayatdavoudi, Parichehr; Sadeghnia, Hamid-Reza; Mohamadian-Roshan, Nema; Hadjzadeh, Mousa AL-Reza

Beneficial Effects of Selective Orexin-A Receptor Antagonist in 4-aminopyridine-induced Seizures in Male Rats

Document Type : Original Article

Authors

¹ Department of Physiology, Neurocognitive Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

² Department of Pharmacology, Pharmacological Research Center of Medicinal Plants, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

³ Department of Pathology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Background: Orexins are excitatory neuropeptides which stimulate the central regulatory pathways. Orexins increase the penicillin-induced epileptic activity in rats. Orexin-A increases in different types of seizures and its elevated level is the characteristic feature in the epileptic children during polysomnography. Recently, the orexin receptor blockage has been reported to increase seizure threshold in mice; however, effect of the selective orexin-A receptor antagonist (SB-334867) on 4-aminopyridine (4-AP)-induced seizures has not been investigated. Materials and Methods: We used the intraperitoneal injection of 4-AP to induce seizure in male rats. Under urethane anesthesia, SB-334867 (50 and 100 nmol) was injected stereotaxically into the ventral hippocampal commissure. Using video recording, the effects of SB-334867 on electroencephalogram and tonic–clonic convulsions were compared to those that received diazepam or dimethyl sulfoxide (DMSO). Results: SB-334867 significantly decreased the duration of spike trains compared to DMSO-treated rats (P < 0.001) and reduced the duration of convulsive seizures (P < 0.05). Seizure onset was increased significantly by SB-334867, 50 nmol, compared to DMSO (P < 0.05) and diazepam (P < 0.01) treated rats. Conclusion: Antagonism of orexin-A receptor by a low-dose SB-334867 showed protective effects in 4-AP-induced seizure-like activities in anesthetized rats.

Keywords

References

1.	Tsujino N, Sakurai T. Orexin/hypocretin: A neuropeptide at the interface of sleep, energy homeostasis, and reward system. Pharmacol Rev 2009;61:162-76.
2.	Kilduff TS, Peyron C. The hypocretin/orexin ligand-receptor system: Implications for sleep and sleep disorders. Trends Neurosci 2000;23:359-65. [PUBMED]
3.	Samson WK, Bagley SL, Ferguson AV, White MM. Orexin receptor subtype activation and locomotor behaviour in the rat. Acta Physiol (Oxf) 2010;198:313-24. [PUBMED]
4.	Hagan JJ, Leslie RA, Patel S, Evans ML, Wattam TA, Holmes S, et al. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci U S A 1999;96:10911-6. [PUBMED]
5.	Samson WK, Bagley SL, Ferguson AV, White MM. Hypocretin/orexin type 1 receptor in brain: Role in cardiovascular control and the neuroendocrine response to immobilization stress. Am J Physiol Regul Integr Comp Physiol 2007;292:R382-7.
6.	Thorpe AJ, Doane DF, Sweet DC, Beverly JL, Kotz CM. Orexin A in the rostrolateral hypothalamic area induces feeding by modulating GABAergic transmission. Brain Res 2006;1125:60-6. [PUBMED]
7.	Kortunay S, Erken HA, Erken G, Genç O, Sahiner M, Turgut S, et al. Orexins increase penicillin-induced epileptic activity. Peptides 2012;34:419-22.
8.	Morales A, Bonnet C, Bourgoin N, Touvier T, Nadam J, Laglaine A, et al. Unexpected expression of orexin-B in basal conditions and increased levels in the adult rat hippocampus during pilocarpine-induced epileptogenesis. Brain Res 2006;1109:164-75. [PUBMED]
9.	Rejdak K, Papuc E, Grieb P, Stelmasiak Z. Decreased cerebrospinal fluid hypocretin-1 (orexin A) in patients after repetitive generalized tonic-clonic seizures. Epilepsia 2009;50:1641-4.
10.	Kacinski M, Budziszewska B, Lason W, Zajac A, Skowronek-Bala B, Leskiewicz M, et al. Level of S100B protein, neuron specific enolase, orexin A, adiponectin and insulin-like growth factor in serum of pediatric patients suffering from sleep disorders with or without epilepsy. Pharmacol Rep 2012;64:1427-33.
11.	Dias MB, Li A, Nattie EE. Antagonism of orexin receptor-1 in the retrotrapezoid nucleus inhibits the ventilatory response to hypercapnia predominantly in wakefulness. J Physiol 2009;587(Pt 9):2059-67.
12.	Goudarzi E, Elahdadi Salmani M, Lashkarbolouki T, Goudarzi I. Hippocampal orexin receptors inactivation reduces PTZ induced seizures of male rats. Pharmacol Biochem Behav 2015;130:77-83. [PUBMED]
13.	Socala K, Szuster-Ciesielska A, Wlaz P. SB 334867, a selective orexin receptor type 1 antagonist, elevates seizure threshold in mice. Life Sci 2016;150:81-8.
14.	Roundtree HM, Simeone TA, Johnson C, Matthews SA, Samson KK, Simeone KA. Orexin receptor antagonism improves sleep and reduces seizures in Kcna1-null mice. Sleep 2016;39:357-68. [PUBMED]
15.	Wahab A, Albus K, Gabriel S, Heinemann U. In search of models of pharmacoresistant epilepsy. Epilepsia 2010;51 Suppl 3:154-9. [PUBMED]
16.	Lu YJ, Zhou J, Zhang SM, Zhang HY, Zheng XX. Inhibitory effects of jujuboside A on EEG and hippocampal glutamate in hyperactive rat. J Zhejiang Univ Sci B 2005;6:265-71. [PUBMED]
17.	Paxinos G, Watson C, editors. The Rat Brain in Stereotaxic Coordinates. 6^th ed. London: Elsevier Academic Press; 2007.
18.	Baracskay P, Kiglics V, Kékesi KA, Juhász G, Czurkó A. Status epilepticus affects the gigantocellular network of the pontine reticular formation. BMC Neurosci 2009;10:133.
19.	Yu W, Smith AB, Pilitsis J, Shin DS. Isovaline attenuates epileptiform activity and seizure behavior in 4-aminopyridine treated rats. Epilepsy Res 2014;108:331-5. [PUBMED]
20.	Sadeghnia HR, Cortez MA, Liu D, Hosseinzadeh H, Snead OC 3^rd. Antiabsence effects of safranal in acute experimental seizure models: EEG and autoradiography. J Pharm Pharm Sci 2008;11:1-14.
21.	Salah A, Perkins KL. Persistent ictal-like activity in rat entorhinal/perirhinal cortex following washout of 4-aminopyridine. Epilepsy Res 2011;94:163-76. [PUBMED]
22.	Kovács A, Mihály A, Komáromi A, Gyengési E, Szente M, Weiczner R, et al. Seizure, neurotransmitter release, and gene expression are closely related in the striatum of 4-aminopyridine-treated rats. Epilepsy Res 2003;55:117-29.
23.	Martín ED, Pozo MA. Valproate suppresses status epilepticus induced by 4-aminopyridine in CA1 hippocampus region. Epilepsia 2003;44:1375-9.
24.	Saito T, Sakamoto K, Koizumi K, Stewart M. Repeatable focal seizure suppression: A rat preparation to study consequences of seizure activity based on urethane anesthesia and reversible carotid artery occlusion. J Neurosci Methods 2006;155:241-50. [PUBMED]
25.	Sakamoto K, Saito T, Orman R, Koizumi K, Lazar J, Salciccioli L, et al. Autonomic consequences of kainic acid-induced limbic cortical seizures in rats: Peripheral autonomic nerve activity, acute cardiovascular changes, and death. Epilepsia 2008;49:982-96. [PUBMED]
26.	Zhang DX, Bertram EH. Suppressing limbic seizures by stimulating medial dorsal thalamic nucleus: Factors for efficacy. Epilepsia 2015;56:479-88. [PUBMED]
27.	Cain DP, Raithby A, Corcoran ME. Urethane anesthesia blocks the development and expression of kindled seizures. Life Sci 1989;44:1201-6. [PUBMED]
28.	Stringer JL. Amygdala stimulation produces two types of hippocampal afterdischarges in the urethane-anesthetized rat. Brain Res 1992;591:103-8. [PUBMED]
29.	Hara K, Harris RA. The anesthetic mechanism of urethane: The effects on neurotransmitter-gated ion channels. Anesth Analg 2002;94:313-8. [PUBMED]
30.	Kukkonen JP. Physiology of the orexinergic/hypocretinergic system: A revisit in 2012. Am J Physiol Cell Physiol 2013;304:C2-32. [PUBMED]
31.	Chou TC, Lee CE, Lu J, Elmquist JK, Hara J, Willie JT, et al. Orexin (hypocretin) neurons contain dynorphin. J Neurosci 2001;21:RC168. [PUBMED]
32.	Li Y, van den Pol AN. Differential target-dependent actions of coexpressed inhibitory dynorphin and excitatory hypocretin/orexin neuropeptides. J Neurosci 2006;26:13037-47. [PUBMED]
33.	Kukkonen JP, Leonard CS. Orexin/hypocretin receptor signalling cascades. Br J Pharmacol 2014;171:314-31. [PUBMED]
34.	Cain SM, Snutch TP. Voltage-gated calcium channels in epilepsy. In: Noebels J, Avoli M, Rogawski M, Olsen R, Delgado-Escueta A, editors. Jasper's Basic Mechanisms of the Epilepsies. 4^th ed. Vancouver: Oxford University Press; 2012.
35.	Smart D, Sabido-David C, Brough SJ, Jewitt F, Johns A, Porter RA, et al. SB-334867-A: The first selective orexin-1 receptor antagonist. Br J Pharmacol 2001;132:1179-82. [PUBMED]
36.	Löscher W. Single versus combinatorial therapies in status epilepticus: Novel data from preclinical models. Epilepsy Behav 2015;49:20-5.
37.	Rajasekaran K, Zanelli SA, Goodkin HP. Lessons from the laboratory: The pathophysiology, and consequences of status epilepticus. Semin Pediatr Neurol 2010;17:136-43. [PUBMED]
38.	Kebe B, Obeten E, Mfem C, Usun O. Comparative studies of the effect of diazepam and magnetic sulphate on motor coordination and seizures in 4-aminopyridine induced seizures in swiss mice. Glob J Sci Front Res C Biol Sci 2016;16:1-13.
39.	Sharma AK, Reams RY, Jordan WH, Miller MA, Thacker HL, Snyder PW. Mesial temporal lobe epilepsy: Pathogenesis, induced rodent models and lesions. Toxicol Pathol 2007;35:984-99. [PUBMED]

Advanced Biomedical Research